Pergi ke luar talian dengan aplikasi Player FM !
01_01 Metastatic Colon Cancer, An Overview of Management and Fundamentals of Systemic Therapy
Manage episode 324500958 series 3335024
1. Clinical presentations of metastatic colon cancer
2. ECOG performance status
3. 5-fluorouracil and capecitabine
4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives)
5. FOLFOXIRI
6. Considerations for elderly/frail patients
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode
1. Cremolini C, et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9
2. Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9
3. Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368
4. Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653
5. Loriot MA, et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001
6. Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533
7. Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302
8. Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928
9. Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113
10. Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904
11. Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457
12. Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033
13. Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1
14. de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808
15. O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142
16. Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
48 episod
01_01 Metastatic Colon Cancer, An Overview of Management and Fundamentals of Systemic Therapy
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 324500958 series 3335024
1. Clinical presentations of metastatic colon cancer
2. ECOG performance status
3. 5-fluorouracil and capecitabine
4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives)
5. FOLFOXIRI
6. Considerations for elderly/frail patients
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode
1. Cremolini C, et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9
2. Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9
3. Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368
4. Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653
5. Loriot MA, et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001
6. Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533
7. Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302
8. Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928
9. Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113
10. Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904
11. Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457
12. Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033
13. Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1
14. de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808
15. O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142
16. Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
48 episod
Kaikki jaksot
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.